Commensal gut microbes stimulate antiviral signals in non-immune lung cells to protect against the flu virus during early stages of infection, researchers report July 2nd in the journal Cell Reports. Enhanced baseline type I interferon (IFNα/β) signaling, which drives antiviral responses, reduced flu virus replication and weight loss in mice, but this protective effect was attenuated by antibiotic treatment.
"This study supports that taking antibiotics inappropriately not only promotes antibiotic resistance and wipes out the commensals in your gut that are useful and protective, but it may also render you more susceptible to viral infections," says senior study author Andreas Wack of the Francis Crick Institute in the UK. "In some countries, the livestock industry uses antibiotics a lot, prophylactically, so treated animals may become more susceptible to virus infections."
IFNα/β signalling plays a central role in the immune defense against viral infections. These pathways are fine-tuned to elicit antiviral protection while avoiding tissue damage due to inflammation. This trade-off is apparent in individuals with a genetic variant that results in high interferon production. They can mount enhanced immune responses against viruses, but the flip side is that they show signs of chronic auto-inflammation. It has not been clear exactly how IFNα/β signalling strikes the right balance, maximizing antiviral protection while minimizing excessive inflammation.
To address this question, Wack and his team used mice with enhanced baseline IFNα/β signalling due to a mutation that increases expression levels of the IFNα/β receptor. These mice were more resistant to influenza virus infection, with less weight loss, lower virus gene expression eight hours after infection, and reduced influenza virus replication two days later. Given that the viral load was controlled early, subsequent IFNα/β signalling and antiviral immune responses were never fully set in motion. The results suggest that regulating expression levels of the IFNα/β receptor could be key to fine-tuning IFNα/β signalling in the lungs.
But the protective effect of enhanced baseline IFNα/β signalling was reduced by two to four weeks of antibiotic treatment, which decreased IFNα/β signalling mainly in lung stromal cells -- non-immune cells that make up the structural tissue of organs. Conversely, fecal transplant reversed the antibiotic-induced susceptibility to influenza virus infection, suggesting a potential role for gut microbes.
Taken together, the results suggest that microbiota increase IFNα/β signalling in lung stromal cells, thereby enhancing protection against influenza virus infection. The new findings are consistent with those from previous studies showing that mice treated with oral antibiotics are more susceptible to viral infections, including the influenza A virus.
"This and previous studies demonstrate that microbiota-driven signals can act at multiple levels, inducing an antiviral state in non-immune cells to control infection early on, and enhancing the functionality of immune cells later in infection," says Wack.
Moving forward, the researchers plan to further investigate the exact origins and mechanisms underlying microbiota-driven antiviral resistance. "Previous research has suggested that the microbiota-driven signal in lung stromal cells could originate either from the gut or the lung," Wack says. "However, in the work presented here, the results of the fecal transplant experiments strongly suggest a gut involvement in this effect. We would love to understand the exact nature of the signal from the gut to the lung, and we are working on several hypotheses."
This study was supported by the Francis Crick Institute, which receives its core funding from Cancer Research UK, the UK Medical Research Council, and the Wellcome Trust. Additional support was provided by the MRC and Deutsche Forschungsgemeinschaft.
Cell Reports, Bradley and Finsterbusch et al.: "Microbiota-driven tonic interferon signals in lung stromal cells protect from influenza virus infection" https://www.cell.com/cell-reports/fulltext/S2211-1247(19)30744-2
Cell Reports (@CellReports), published by Cell Press, is a weekly open-access journal that publishes high-quality papers across the entire life sciences spectrum. The journal features reports, articles, and resources that provide new biological insights, are thought-provoking, and/or are examples of cutting-edge research. Visit: http://www.cell.com/cell-reports. To receive Cell Press media alerts, contact firstname.lastname@example.org.